capd/dpca 19 sleep safe
fresenius medical care australia pty ltd (nz) - calcium chloride dihydrate 0.1838 g/l; ; ; glucose monohydrate 16.5 g/l equivalent to glucose anhydrous 15 g/l; ; ; ; magnesium chloride hexahydrate 0.1017 g/l; ; ; sodium chloride 5.786 g/l; ; ; ; sodium lactate 3.925 g/l (as 50% solution); - dialysis solution - active: calcium chloride dihydrate 0.1838 g/l glucose monohydrate 16.5 g/l equivalent to glucose anhydrous 15 g/l magnesium chloride hexahydrate 0.1017 g/l sodium chloride 5.786 g/l sodium lactate 3.925 g/l (as 50% solution) excipient: hydrochloric acid sodium hydroxide water for injection
capd/dpca 17 andy disc
fresenius medical care australia pty ltd (nz) - calcium chloride dihydrate 0.1838 g/l; ; glucose monohydrate 16.5 g/l equivalent to glucose anhydrous 15 g/l; ; ; ; magnesium chloride hexahydrate 0.1017 g/l; ; sodium chloride 5.786 g/l; ; ; sodium lactate 3.925 g/l (as 50% solution); - dialysis solution - active: calcium chloride dihydrate 0.1838 g/l glucose monohydrate 16.5 g/l equivalent to glucose anhydrous 15 g/l magnesium chloride hexahydrate 0.1017 g/l sodium chloride 5.786 g/l sodium lactate 3.925 g/l (as 50% solution) excipient: hydrochloric acid sodium hydroxide water for injection
capd/dpca 17 sleep safe
fresenius medical care australia pty ltd (nz) - calcium chloride dihydrate 0.1838 g/l; ; ; glucose monohydrate 16.5 g/l equivalent to glucose anhydrous 15 g/l; ; ; ; magnesium chloride hexahydrate 0.1017 g/l; ; ; sodium chloride 5.786 g/l; ; ; ; sodium lactate 3.925 g/l (as 50% solution); - dialysis solution - active: calcium chloride dihydrate 0.1838 g/l glucose monohydrate 16.5 g/l equivalent to glucose anhydrous 15 g/l magnesium chloride hexahydrate 0.1017 g/l sodium chloride 5.786 g/l sodium lactate 3.925 g/l (as 50% solution) excipient: hydrochloric acid sodium hydroxide water for injection
capd/dpca 18 sleep safe
fresenius medical care australia pty ltd (nz) - calcium chloride dihydrate 0.1838 g/l; ; ; glucose monohydrate 16.5 g/l equivalent to glucose anhydrous 15 g/l; ; ; ; magnesium chloride hexahydrate 0.1017 g/l; ; ; sodium chloride 5.786 g/l; ; ; ; sodium lactate 3.925 g/l (as 50% solution); - dialysis solution - active: calcium chloride dihydrate 0.1838 g/l glucose monohydrate 16.5 g/l equivalent to glucose anhydrous 15 g/l magnesium chloride hexahydrate 0.1017 g/l sodium chloride 5.786 g/l sodium lactate 3.925 g/l (as 50% solution) excipient: hydrochloric acid sodium hydroxide water for injection
calcium acetate capsule
hikma pharmaceuticals usa inc. - calcium acetate (unii: y882yxf34x) (calcium cation - unii:2m83c4r6zb) - calcium acetate 667 mg - calcium acetate is a phosphate binder indicated to reduce serum phosphorus in patients with end stage renal disease (esrd). patients with hypercalcemia. pregnancy category c: calcium acetate capsules contains calcium acetate. animal reproduction studies have not been conducted with calcium acetate, and there are no adequate and well controlled studies of calcium acetate use in pregnant women. patients with end stage renal disease may develop hypercalcemia with calcium acetate treatment [see warnings and precautions (5.1)] . maintenance of normal serum calcium levels is important for maternal and fetal well being. hypercalcemia during pregnancy may increase the risk for maternal and neonatal complications such as stillbirth, preterm delivery, and neonatal hypocalcemia and hypoparathyroidism. calcium acetate treatment, as recommended, is not expected to harm a fetus if maternal calcium levels are properly monitored during and following treatment. the effects of calcium acetate on labor and delivery are unknown.
calcium acetate tablet
camber pharmaceuticals, inc. - calcium acetate (unii: y882yxf34x) (calcium cation - unii:2m83c4r6zb) - calcium acetate 667 mg - calcium acetate is a phosphate binder indicated to reduce serum phosphorus in patients with end stage renal disease (esrd). patients with hypercalcemia. pregnancy category c calcium acetate tablets contain calcium acetate. animal reproduction studies have not been conducted with calcium acetate, and there are no adequate and well controlled studies of calcium acetate use in pregnant women. patients with end stage renal disease may develop hypercalcemia with calcium acetate treatment [see warnings and precautions (5.1)]. maintenance of normal serum calcium levels is important for maternal and fetal well being. hypercalcemia during pregnancy may increase the risk for maternal and neonatal complications such as stillbirth, preterm delivery, and neonatal hypocalcemia and hypoparathyroidism. calcium acetate treatment, as recommended, is not expected to harm a fetus if maternal calcium levels are properly monitored during and following treatment. the effects of calcium acetate on labor and delivery are unknown. a c
calcium acetate capsule
remedyrepack inc. - calcium acetate (unii: y882yxf34x) (calcium cation - unii:2m83c4r6zb) - calcium acetate 667 mg - calcium acetate capsule is a phosphate binder indicated to reduce serum phosphorus in patients with end stage renal disease (esrd). patients with hypercalcemia. pregnancy category c calcium acetate capsules contain calcium acetate. animal reproduction studies have not been conducted with calcium acetate, and there are no adequate and well controlled studies of calcium acetate use in pregnant women. patients with end stage renal disease may develop hypercalcemia with calcium acetate treatment [see warnings and precautions (5.1)]. maintenance of normal serum calcium levels is important for maternal and fetal well being. hypercalcemia during pregnancy may increase the risk for maternal and neonatal complications such as stillbirth, preterm delivery, and neonatal hypocalcemia and hypoparathyroidism. calcium acetate treatment, as recommended, is not expected to harm a fetus if maternal calcium levels are properly monitored during and following treatment. the effects of calcium acetate on labor and d
calcium acetate capsule
lupin pharmaceuticals, inc. - calcium acetate (unii: y882yxf34x) (calcium cation - unii:2m83c4r6zb) - calcium acetate 667 mg - calcium acetate capsule is a phosphate binder indicated to reduce serum phosphorus in patients with end stage renal disease (esrd). patients with hypercalcemia. pregnancy category c calcium acetate capsules contain calcium acetate. animal reproduction studies have not been conducted with calcium acetate, and there are no adequate and well controlled studies of calcium acetate use in pregnant women. patients with end stage renal disease may develop hypercalcemia with calcium acetate treatment [see warnings and precautions (5.1)]. maintenance of normal serum calcium levels is important for maternal and fetal well being. hypercalcemia during pregnancy may increase the risk for maternal and neonatal complications such as stillbirth, preterm delivery, and neonatal hypocalcemia and hypoparathyroidism. calcium acetate treatment, as recommended, is not expected to harm a fetus if maternal calcium levels are properly monitored during and following treatment. the effects of calcium acetate on labor and delivery are unk
calcium acetate capsule
lupin limited - calcium acetate (unii: y882yxf34x) (calcium cation - unii:2m83c4r6zb) - calcium acetate 667 mg - calcium acetate capsule is a phosphate binder indicated to reduce serum phosphorus in patients with end stage renal disease (esrd). patients with hypercalcemia. pregnancy category c calcium acetate capsules contain calcium acetate. animal reproduction studies have not been conducted with calcium acetate, and there are no adequate and well controlled studies of calcium acetate use in pregnant women. patients with end stage renal disease may develop hypercalcemia with calcium acetate treatment [see warnings and precautions (5.1) ]. maintenance of normal serum calcium levels is important for maternal and fetal well being. hypercalcemia during pregnancy may increase the risk for maternal and neonatal complications such as stillbirth, preterm delivery, and neonatal hypocalcemia and hypoparathyroidism. calcium acetate treatment, as recommended, is not expected to harm a fetus if maternal calcium levels are properly monitored during and following treatment. the effects of calcium acetate on labor and delivery are un
calcium acetate capsule
eci pharmaceuticals, llc - calcium acetate (unii: y882yxf34x) (calcium cation - unii:2m83c4r6zb) - calcium acetate 667 mg - calcium acetate is a phosphate binder indicated to reduce serum phosphorus in patients with end stage renal disease (esrd). patients with hypercalcemia. pregnancy category c calcium acetate contains calcium acetate. animal reproduction studies have not been conducted with calcium acetate, and there are no adequate and well controlled studies of calcium acetate use in pregnant women. patients with end stage renal disease may develop hypercalcemia with calcium acetate treatment [ see warnings and precautions (5.1) ] . maintenance of normal serum calcium levels is important for maternal and fetal well being. hypercalcemia during pregnancy may increase the risk for maternal and neonatal complications such as stillbirth, preterm delivery, and neonatal hypocalcemia and hypoparathyroidism. calcium acetate treatment, as recommended, is not expected to harm a fetus if maternal calcium levels are properly monitored during and following treatment. the effects of calcium acetate on labor and delivery are unknown. calciu